[Atrial fibrillation in patients with heart failure. Pathophysiological concepts and therapeutic options].
Boldt
L-H
LH
Medizinische Klinik mit Schwerpunkt Kardiologie, Campus Virchow Klinikum, Charité Universitätsmedizin Berlin. leif-hendrik.boldt@charite.de
Rolf
S
S
Dietz
R
R
Haverkamp
W
W
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000638:Amiodarone / Q000627:therapeutic use; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000453:epidemiology / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy; D017115:Catheter Ablation; D005858:Germany / Q000453:epidemiology; D006333:Heart Failure / Q000150:complications* / Q000453:epidemiology / Q000503:physiopathology / Q000628:therapy; D006801:Humans; D009490:Neurosecretory Systems / Q000187:drug effects; D015995:Prevalence; D011788:Quality of Life; D012307:Risk Factors
D000319:Adrenergic beta-Antagonists; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000889:Anti-Arrhythmia Agents; D000638:Amiodarone